Avantor: The Q4 Dip Could Have Priced In All The Negatives

Avantor is a turnaround play in life sciences distribution and manufacturing, trading at a historically low valuation after a 50% stock decline. New management is executing a Revival program targeting $400M in cost savings, debt reduction, and organizational restructuring to restore growth and margins. 2026 guidance remains cautious, with revenue and adjusted EPS expected to decline, but stabilization and growth are anticipated in 2027.

Seeking Alpha • 9 hours ago

New Strong Sell Stocks for February 17th

AVTR, CMCO and KHC have been added to the Zacks Rank #5 (Strong Sell) List on February 17th, 2026.

Zacks Investment Research • Feb 17, 2026

AVTR Stock Plunges Despite Q4 Earnings Beat Estimates, Margins Decline

Avantor stock sinks 13% as Q4 earnings beat estimates, but revenues slip, margins contract and 2026 outlook signals more pressure ahead.

Zacks Investment Research • Feb 12, 2026

Avantor Falls To Critical Levels As CEO Signals Investment Year Amid Soft Guidance

• Avantor shares are approaching critical lows. Why is AVTR stock at lows?

Benzinga • Feb 11, 2026

Avantor, Inc. (AVTR) Q4 2025 Earnings Call Transcript

Avantor, Inc. (AVTR) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 11, 2026

Avantor® Reports Fourth Quarter and Full Year 2025 Results

Revival program underway, including relaunch of VWR brand, implementation of critical manufacturing and supply chain improvements, and upgrades to e-commerce channel Fourth Quarter 2025 Net sales of $1.66 billion, decrease of 1%; organic decrease of 4% Net income of $52 million; Adjusted EBITDA of $252 million Diluted GAAP EPS of $0.08; adjusted EPS of $0.22 Operating cash flow of $153 million; free cash flow of $117 million Full Year 2025 Net sales of $6.55 billion, decrease of 3%; organic decline of 3% Net loss of $530 million; Adjusted EBITDA of $1,069 million Diluted GAAP loss per share of $0.78; adjusted EPS of $0.90 Operating cash flow of $624 million; free cash flow of $496 million RADNOR, Pa., Feb. 11, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its fourth fiscal quarter and year ended December 31, 2025.

PRNewsWire • Feb 11, 2026

Avantor, Inc. (AVTR) Surpasses Q4 Earnings and Revenue Estimates

Avantor, Inc. (AVTR) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.27 per share a year ago.

Zacks Investment Research • Feb 11, 2026

Avantor (AVTR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Avantor (AVTR) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Feb 11, 2026

Should Value Investors Buy Avantor (AVTR) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Feb 6, 2026

AVTR or ALHC: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical Services sector have probably already heard of Avantor, Inc. (AVTR) and Alignment Healthcare (ALHC). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Feb 5, 2026